CoChat

Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform

Open access
Palmqvist, Sebastian, Warmenhoven, Noëlle, Anastasi, Federica, Pilotto, Andrea, Janelidze, Shorena, Tideman, Pontus, Stomrud, Erik, Mattsson-Carlgren, Niklas, Smith, Ruben, Ossenkoppele, Rik, Tan, Kübra, Dittrich, Anna, Skoog, Ingmar, Zetterberg, Henrik, Quaresima, Virginia, Tolassi, Chiara, Höglund, Kina, Brugnoni, Duilio, Puig-Pijoan, Albert, Fernández-Lebrero, Aida, Contador, José, Padovani, Alessandro, Monane, Mark, Verghese, Philip B., Braunstein, Joel B., Kern, Silke, Blennow, Kaj, Ashton, Nicholas J., Suárez-Calvet, Marc, Hansson, Oskar · 2025 · Nature Medicine
Cited by 194

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93–0.96. In secondary care, the accuracies were 89–91%, the positive predictive values 89–95% and the negative predictive values 77–90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92–94% in secondary and primary care, excluding 12–17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-025-03622-w

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 194

Metadata

Authors
Palmqvist, S., Warmenhoven, N., Anastasi, F., Pilotto, A., Janelidze, S., Tideman, P., Stomrud, E., Mattsson-Carlgren, N., Smith, R., Ossenkoppele, R., Tan, K., Dittrich, A., Skoog, I., Zetterberg, H., Quaresima, V., Tolassi, C., Höglund, K., Brugnoni, D., Puig-Pijoan, A., Fernández-Lebrero, A., Contador, J., Padovani, A., Monane, M., Verghese, P. B., Braunstein, J. B., Kern, S., Blennow, K., Ashton, N. J., Suárez-Calvet, M., & Hansson, O.
Venue
Nature Medicine
Published
2025-04-09
Volume
31
Issue
6
Pages
2036-2043
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4409279344
Cited by
194
References
18
FWCI
120.78
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform. https://app.cochat.ai/papers/10.1038/s41591-025-03622-w
The paper
Palmqvist, S., Warmenhoven, N., Anastasi, F., Pilotto, A., Janelidze, S., Tideman, P., Stomrud, E., Mattsson-Carlgren, N., Smith, R., Ossenkoppele, R., Tan, K., Dittrich, A., Skoog, I., Zetterberg, H., Quaresima, V., Tolassi, C., Höglund, K., Brugnoni, D., Puig-Pijoan, A., . . . Hansson, O. (2025). Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform. Nature Medicine. https://doi.org/10.1038/s41591-025-03622-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.